Induction of Clinical Response Using Rifaximin in Crohn's Disease
A Randomized, Prospective, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohn's Disease
Sponsor: Bausch Health Americas, Inc.
A PHASE2 clinical study on Crohn's Disease, this trial is completed. The trial is conducted by Bausch Health Americas, Inc. and has accumulated 14 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Completed PHASE2
-
Apr 2021 — Jan 2022 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Jan 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Sep 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bausch Health Americas, Inc.
- Scott Lee
For direct contact, visit the study record on ClinicalTrials.gov .